Clinical Trial Evaluating the Safety and Efficacy of Levamisole in Loa Loa Microfilaremic Patients

Inclusion Criteria: * Written consent written, signed (or with thumbprint) and dated * Aged 18 to 65 inclusive * Individual microfilarial density ≥ 1mf/mL * Body weight ≥ 40 kg in women and ≥ 45 kg in men; and less than 85 kg * In good health condition, as determined by the medical questionnaire and the general clinical examination: absence of acute or chronic infection Exclusion Criteria: * Participation in any study other than purely observational, in the 4 weeks preceding this study (determined by the theoretical date of administration of LEV or placebo). * Any vaccination in the 4 weeks preceding this study. * Acute infection requiring a treatment in the 10 days preceding this study, determined by the anamnesis during the medical interview (example: pulmonary infection, ENT, digestive, cutaneous, with implementation of an antibiotic treatment or not) * Warfarin treatment * Treatment with clozapine, phenythiazines, sulfasalazine, carbamazepine, synthetic antithyroid, ticlopidine, cimetidine, and gold salts: whether it is a long-term treatment, or a treatment given in a single dose 10 days before the start of treatment for the clinical trial (precaution of use compared to the risk of agranulocytosis of immuno-allergic or toxic origin) * Known immunosuppressive pathology * Past or current history of neurological (including epilepsy) or neuropsychiatric disease * History of agranulocytosis * Consumption of alcohol, taking cocaine or other drugs of abuse in the 72 hours pre…